Vaishali Pharma (VAISHALI) Q1 26/27 earnings summary

Executive summary

• Board approved unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, along with the limited review reports from statutory auditors.

• Annual Report and Director's Report for FY 2025-26 were approved, and the 19th AGM is scheduled for 24 September 2026 via video conferencing.

• Appointment of scrutinizer for remote e-voting at the AGM was confirmed.

Financial highlights

• Standalone revenue from operations for Q1 FY27 was ₹2,289.14 lakh, compared to ₹2,374.71 lakh in Q1 FY26 and ₹2,692.71 lakh in Q4 FY26.

• Standalone net profit for Q1 FY27 was ₹148.97 lakh, up from ₹127.93 lakh in Q1 FY26 but down from ₹26.64 lakh in Q4 FY26.

• Consolidated revenue from operations for Q1 FY27 was ₹2,289.14 lakh, with consolidated net profit at ₹154.54 lakh, including a ₹5.65 lakh share of profit from the associate.

• Basic and diluted EPS for Q1 FY27 were ₹0.11 (standalone) and ₹0.12 (consolidated).

Outlook and guidance

• No explicit forward-looking guidance provided, but the inclusion of the associate's results from September 2025 is expected to impact future consolidated performance.